# Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)

> **NCT00815568** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 114 (estimated)

## Conditions studied

- AML
- MDS
- ALL
- CML
- Lymphoma

## Interventions

- **DRUG:** fludarabine phosphate, busulfan

## Key facts

- **NCT ID:** NCT00815568
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-08
- **Primary completion:** 2011-12
- **Final completion:** 2012-12
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2008-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00815568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00815568, "Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00815568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*